Further studies demonstrated that cancer cell triggered ERK1/2 phosphorylation could also be inhibited by knockdown of the A3R by siRNA or by downregulating the receptor following prolonged exposure to the ligand, i.e., Cl-IBMECA [20]. The gene discussed is MAPK3; the disease is cancer.